Hepatocellular carcinoma

Josep M. Llovet(Institució Catalana de Recerca i Estudis Avançats), Robin Kate Kelley(University of California, San Francisco), Augusto Villanueva(Icahn School of Medicine at Mount Sinai), Amit G. Singal(The University of Texas Southwestern Medical Center), Eli Pikarsky(Hebrew University of Jerusalem), Sasan Roayaie(White Plains Hospital), Riccardo Lencioni(University of Pisa), Kazuhiko Koike(University of Tokyo Hospital), Jessica Zucman‐Rossi(Inserm), Richard S. Finn(University of California, Los Angeles)

Nature Reviews Disease Primers

January 21, 2021

10.1038/s41572-020-00240-3

Cited by 6,376Open Access

Abstract

Related Papers

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al.|New England Journal of Medicine|2008|12.9k

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Lola Rahib, Benjamin D. Smith, Rhonda Aizenberg et al.|Cancer Research|2014|7.2k

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Josep M. Llovet, Jordi Bruix|Hepatology|2003|3k

Global Epidemiology of Hepatocellular Carcinoma

Katherine A. McGlynn, Jessica L. Petrick, W. Thomas London|Clinics in Liver Disease|2015|919

Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease

Sahil Mittal, Hashem B. El‐Serag, Yvonne H. Sada et al.|Clinical Gastroenterology and Hepatology|2015|638